RJA
RETA

Raymond James & Associates’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Raymond James & Associates’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,156
Closed -$744K – 3691
2020
Q1 		$744K Buy
5,156
+3,106
+152% +$600K ﹤0.01% 2167
2019
Q4 		$419K Sell
2,050
-2,240
-52% -$409K ﹤0.01% 2859
2019
Q3 		$344K Buy
4,290
+150
+4% +$12.7K ﹤0.01% 2926
2019
Q2 		$391K Buy
+4,140
New +$357K ﹤0.01% 2839

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's RETA Position: Q2 2020 in Review

Raymond James & Associates sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 5,156 shares — an estimated $744K sold.

Raymond James & Associates first reported a position in RETA in Q2 2019 and held it in 4 quarters. The position peaked at $744K in Q1 2020. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

  • Raymond James & Associates reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
  • Raymond James & Associates sold 5,156 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $744K.
  • Raymond James & Associates first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 4 quarters.
  • Raymond James & Associates's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $744K in Q1 2020.
  • 207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Raymond James & Associates's 13F filing for Q2 2020, filed 28 Jul 2020.